Dr. Lara on the Potential Role of IDO Inhibitors in the Treatment of RCC

Primo N. Lara, MD
Published: Monday, Jul 31, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma (RCC).

The advances of an IDO inhibitor such as epacadostat is that it is well tolerated, says Lara. In a phase Ib/II trial, it did not increase the toxicity of the base PD-1 inhibitor pembrolizumab (Keytruda).


Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma (RCC).

The advances of an IDO inhibitor such as epacadostat is that it is well tolerated, says Lara. In a phase Ib/II trial, it did not increase the toxicity of the base PD-1 inhibitor pembrolizumab (Keytruda).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x